Emmaus Life Sciences Inc. (EMMA)
Emmaus Life Sciences Reports Delayed Filing of Annual Report
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences recibe la autorización de comercialización para Puerto Rico
/PRNewswire-HISPANIC PR WIRE/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), líder en el tratamiento de la anemia falciforme, también denominada enfermedad de...
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing...
Emmaus Life Sciences Reports Q3 2023 Financial Results
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Reports Management Changes
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Reports Q2 2023 Financial Results
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Provides Interim Shipment Data
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Dr. Niihara Meets with Local Indian Governor
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...
Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...
Endari® Receives Kuwaiti Marketing Authorization
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration...
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences to Present at Investor Conferences in May
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...